Terminated NA INTERVENTIONAL 1-arm NCT02042053

PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients

Sponsor: Dendreon

Conditions Prostate Cancer

Interventions PET/CT PET/MRI

Updated 8 times since 2017 Last updated: Jul 13, 2017 Started: Jan 31, 2014 Primary completion: May 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to PI leaving the institution

Other terminated trials from Dendreon

See all terminations from Dendreon

Other Prostate Cancer trials with similar outcome

Browse all Prostate Cancer trials

A NA clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Dendreon and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2019 — Jan 2021 [monthly]

Terminated NA
Jun 2018 — Jun 2019 [monthly]

Terminated NA

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Terminated NA
Feb 2017 — Aug 2017 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dendreon
NYU Langone Health

Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States